NCT05040828

Early Intervention in Allergic Patients

Early Intervention With Leukotriene Receptor Antagonists in Patients With Grass Pollinosis: Effects on Clinical Symptoms and Allergic Inflammation

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: Beijing Tongren Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 59 Years
• Healthy volunteers: Not accepted

Summary

As many as 250 million people suffer from allergic rhinitis in China, which has a large population, early use of drugs may help better control the symptoms.This study aimed to investigate the effects of early interventional treatment with the leukotriene receptor antagonist (LTRA) montelukast on seasonal allergic rhinitis.

Conditions

• Allergic Rhinitis Due to Weed Pollen
• Montelukast

Interventions

Type	Name	Description
BEHAVIORAL	Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.	Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
BEHAVIORAL	Montelukast Sodium Tablets 10mg quaque die orally was administered after peak pollen count.	10mg quaque die orally was administered after peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
DRUG	No oral drug therapy throughout the pollen period	Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.

Timeline

• Start date: 2020-07-01
• Primary completion: 2020-09-30
• Completion: 2020-11-10
• First posted: 2021-09-10
• Last updated: 2021-09-10

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study